Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation Research. 2007;100:1405-1407
doi: 10.1161/01.RES.0000269683.67849.b1
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szmitko, P. E.
Right arrow Articles by Verma, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szmitko, P. E.
Right arrow Articles by Verma, S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NITRIC OXIDE
Related Collections
Right arrowRelated Article
(Circulation Research. 2007;100:1405.)
© 2007 American Heart Association, Inc.

Editorials

C-Reactive Protein and Reendothelialization

NO Involvement

Paul E. Szmitko, Subodh Verma

From the Division of Cardiac Surgery, St. Michael’s Hospital (S.V.) and the Division of General Internal Medicine (P.E.S.), University of Toronto, Canada.

Correspondence to Subodh Verma, MD, PhD, Division of Cardiac Surgery, Suite 8–003F, Bond Wing, St. Michael’s Hospital, 30 Bond Street, Toronto, Ontario, Canada, M5B 1W8. E-mail subodh.verma{at}sympatico.ca



See related article, pages 1452–1459


Key Words: Key Words: • C-reactive protein • nitric oxide • reendothelialization

Disruption of the endothelium and its subsequent dysfunction appears to set the stage for atherogenesis.1 The maintenance of vascular homeostasis depends in part on a balance between endothelium-derived relaxing and contracting factors. Alterations in this balance lead to inflammation and the formation of fatty streaks and fibrous plaques. The diminished production or availability of nitric oxide (NO) appears paramount to setting the stage for inflammation and vascular injury.

In addition to its vasodilatory effect on the vasculature, endothelium-derived NO promotes endothelial cell growth, survival and migration,2 stimulates angiogenesis and neovascularization in part by endothelial progenitor cell (EPC) recruitment,3 inhibits leukocyte adhesion to the endothelium,4 maintains vascular smooth muscle in a nonproliferative state,5 and limits platelet aggregation and thrombosis.6 Maintenance of an intact and functional endothelium protects against vascular disease while its disruption is detrimental. The study by Schwartz et al,7 in this issue of Circulation Research, adds to our understanding of how C-reactive protein (CRP) works to promote vascular pathology by inhibiting NO synthesis.

CRP, long regarded as an acute phase protein and an active participant in the innate immune system, has more recently been linked to the development of cardiovascular disease.8 On the basis of several prospective epidemiologic studies, circulating high sensitivity CRP has emerged as an independent predictor of cardiovascular disease risk in various subgroups of patients, including those without overt cardiovascular disease, patients with stable angina or acute coronary syndromes, and in those with the metabolic syndrome.9–12 In primary prevention, CRP confers additional prognostic value at all levels of Framingham risk score and blood pressure.13,14 However, whether or not CRP plays a direct biological role in the initiation and progression of atherosclerosis is controversial.15,16

In vitro studies have supported CRP’s role as a direct mediator of atherogenesis at various stages of disease development, including the earliest stage marked by endothelial dysfunction.1 First and foremost, CRP potently downregulates endothelial nitric oxide synthase (eNOS) protein expression and destabilizes eNOS mRNA, resulting in the decreased release of basal and stimulated NO and enhanced inflammatory cell adhesion.17,18 CRP further disrupts the integrity of the endothelium by its detrimental effect on EPC biology, interfering with EPC differentiation, function and survival, in part by impairing antioxidative processes, increasing the production of reactive oxygen species and promoting apoptosis.19,20 Finally, CRP has a direct pro-inflammatory effect on endothelial cells, inducing expression of ICAM-1 and VCAM-1.21

Criticism surrounding the use of commercial CRP preparations for in vitro studies, namely that some of the findings may be explained by the presence of sodium azide (NaN3) and endotoxin,22,23 have largely been dismissed with demonstration that azide and LPS free CRP elicit similar effects on endothelial activation as previously reported.24 Professor Jialal’s group recently used Toll-like receptor 4 (TLR4) knockdown endothelial cells to specifically answer this question. Human aortic endothelial cells (HAECs) transfected with prevalidated TLR4 small interfering RNA (siRNA) and scrambled siRNA controls were challenged with pleural fluid-derived CRP or LPS for 12 to 16 hour. Secreted interleukin-6 (IL-6), IL-1ß, IL-8, and plasminogen activator inhibitor-1 (PAI-1) levels and eNOS activity were determined. TLR4 knockdown in HAECs significantly decreased LPS-induced IL-1ß, IL-6, and IL-8, whereas the stimulatory effects of CRP were similar in both scrambled control and TLR4 knockdown cells. Furthermore, CRP significantly stimulated PAI-1 levels in both control and TLR4-transfected cells and inhibited eNOS activity, whereas LPS effects were negated in TLR4-transfected cells, clearly supporting a direct biological effect of native CRP.25

To investigate the in vivo actions of CRP on the endothelium and in particular, on reendothelialization, Schwartz and colleagues used mice expressing rabbit CRP under the regulation of the phosphoenolpyruvate carboxykinase promoter, which allows for the manipulation of CRP levels by changing the amount of carbohydrate intake. The same mouse model was used previously to demonstrate that modest elevations in CRP were sufficient to increase systolic blood pressure via the downregulation of vascular angiotensin type 2 receptor expression. The observed effect could be in part reversed by an NO donor, suggesting NO deficiency was involved in CRP-mediated systolic hypertension.26 Thus, the effect of CRP on vascular eNOS expression was further examined with the current set of experiments. Using a carotid injury model, modest elevations in serum CRP levels (9 µg/mL) impaired reendothelialization after 5 days, an effect which was related to a decline in vascular eNOS expression, eNOS mRNA and NOS enzymatic activity. The resulting decrease in bioavailable NO impaired endothelial cell growth and migration. The in vivo findings were consistent with results obtained with ex vivo incubations of mouse carotid arteries with recombinant human CRP, as well as with the earlier in vitro work previously described. Of note, the authors used heat inactivation of the recombinant CRP to further demonstrate that the ex vivo observations were because of the actions of CRP and not of contaminants within the CRP preparations. The authors further show that CRP-responsive elements reside within the eNOS promoter, providing a potential mechanism through which CRP may directly alter eNOS gene expression.

The current in vivo findings linking CRP to impaired endothelium-derived NO production support the observation that elevated CRP levels may result in a greater risk of hypertension because of impaired vasorelaxation and exaggerated vascular responses to stress. Had the authors extended their period of observation beyond 5 days post injury, additional structural changes to the vasculature, and not simply a lack of reendothelialization, may have been observed. It would be interesting to note if chronic exposure to elevated CRP levels in the carotid injury model would result in enhanced neointimal hyperplasia. In fact, our group, using a human CRP transgenic mouse model, has recently shown that chronic CRP elevation in vivo promoted endothelial dysfunction with resultant changes in vascular structure and endothelial responses to injury.27 Macrophage infiltration into the arterial wall and the aortic expression of the chemokine MCP-1 as well as the adhesion protein VCAM-1 were increased in mice with elevated CRP levels. Thus, by promoting endothelial dysfunction in vivo, CRP sets the stage for atherogenesis.

Previous experiments performed in human CRP transgenic mice, demonstrated that human CRP creates a prothrombotic phenotype, as evidenced by higher rates of thrombotic occlusion following arterial injury,28 likely a consequence of reduced NO bioavailability. Furthermore, by crossing CRP transgenic mice with the atherosclerosis prone apoE–/– mice, CRP was shown to accelerate aortic atherosclerotic plaque formation which was associated with increased complement deposition and elevated expression of AT1-R, VCAM-1 and collagen within the lesions.29 However, subsequent studies did not find similar results,30 highlighting the difficulties with using a murine model to examine human disease states.31

Using the aforementioned human CRP transgenic mouse model, Grad et al32 recently demonstrated a similar effect of CRP on NO biology in vivo. Using a femoral artery wire injury model, the authors demonstrated that eNOS protein and mRNA expression were significantly suppressed in the injured arteries of CRP transgenic mice, a change which translated into a measurable reduction in NO release post injury. Thus, reports from two independent groups, using two different CRP transgenic mouse models, reach the same conclusion. CRP modulates eNOS expression and NO metabolism in vivo, paralleling prior investigations in cultured endothelial cells.

The current work by Schwartz et al,7 clearly demonstrates in an in vivo transgenic mouse model that CRP impairs reendothelialization following vascular injury in part by decreasing eNOS gene transcription and activity. The demonstration that CRP-responsive elements reside within the eNOS promoter, provide a potential mechanism through which CRP may directly alter eNOS gene expression. Confirming in vitro findings with in vivo results will no doubt further elucidate the pathogenic role of CRP in vascular disease. It will be interesting to see whether subsequent studies using these in vivo CRP models will confirm other in vitro findings. For example, the lack of reendothelialization mediated by CRP observed in the study by Schwartz et al may have been influenced by impaired EPC recruitment to the area of vascular denudation. As our understanding of how CRP works to promote vascular pathology increases, strategies that combat CRP and promote vascular healing and reendothelialization following invasive procedures may become part of our clinical armamentarium in the treatment of cardiovascular disease. The recent synthesis and characterization of 1,6-bis(phosphocholine)-hexane as a specific small-molecule inhibitor of CRP, with potent cardiovascular protective effects, is one big step in this direction.33


*    Acknowledgments
 
Sources of Funding

Supported by grants from the Heart and Stroke Foundation of Canada, and the Canadian Institutes for Health Research (S. Verma) and The Physicians’ Services Incorporated Foundation (P.E. Szmitko).

Disclosures

Paul E. Szmitko is the recipient of the MerckFrosst Canada Traineeship in Diabetes and Cardiovascular Disease.


*    Footnotes
 
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.


*    References
up arrowTop
 *References
 

  1. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation. Circulation. 2003; 108: 1917–1923.[Free Full Text]
  2. Kawasaki K, Smith RS, Hsieh CM, Sun J, Chao J, Liao JK. Activation of the phophatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol. 2003; 23: 5726–5737.[Abstract/Free Full Text]
  3. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003; 9: 1370–1376.[CrossRef][Medline] [Order article via Infotrieve]
  4. Gauthier TW, Scalia R, Murohara T, Guo JP, Lefer AM. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995; 15: 1652–1659.[Abstract/Free Full Text]
  5. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of camp-dependent protein kinase by cGMP. Am J Physiol. 1994; 267: C1405–C1413.[Medline] [Order article via Infotrieve]
  6. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation. 1992; 85: 2284–2290.[Abstract/Free Full Text]
  7. Schwartz R, Osborne-Lawrence S, Hahner L, Gibson LL, Gormley AK, Vongpatanasin W, Zhu W, Word RA, Seetharam D, Black S, Samols D, Mineo C, Shaul PW. C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res. 2007; 100: 1452–1459.[Abstract/Free Full Text]
  8. Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med. 2005; 2: 29–36.[CrossRef][Medline] [Order article via Infotrieve]
  9. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836–843.[Abstract/Free Full Text]
  10. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G, Maseri A. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999; 99: 855–860.[Abstract/Free Full Text]
  11. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E, Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998; 98: 839–844.[Abstract/Free Full Text]
  12. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8 year follow-up of 14 719 initially healthy Am women. Circulation. 2003; 107: 391–397.[Abstract/Free Full Text]
  13. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and the risk of future cardiovascular events. Circulation. 2003; 108: 994–1000.
  14. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557–1565.[Abstract/Free Full Text]
  15. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006; 113: 2135–2150.[Medline] [Order article via Infotrieve]
  16. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation. 2006; 113: 2128–2134.[Free Full Text]
  17. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002; 106: 913–919.[Abstract/Free Full Text]
  18. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002; 106: 1439–1441.[Abstract/Free Full Text]
  19. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004; 109: 2058–2067.[Abstract/Free Full Text]
  20. Fujii H, Li SH, Szmitko PE, Fedak PW, Verma S. C-Reactive Protein Alters Antioxidant Defenses and Promotes Apoptosis in Endothelial Progenitor Cells. Arterioscler Thromb Vasc Biol. 2006; 26: 2476–2482.[Abstract/Free Full Text]
  21. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: 2165–2168.[Abstract/Free Full Text]
  22. Liu C, Wang S, Deb A, Nath KA, Katusic ZS, McConnell JP, Caplice NM. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circ Res. 2005; 97: 135–143.[Abstract/Free Full Text]
  23. Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, Sabin CA, Zychlinsky A, de Diego J. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res. 2005; 97: e97–e103.[Abstract/Free Full Text]
  24. Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol. 2005; 25: 2216–2221.[Abstract/Free Full Text]
  25. Dasu MR, Devaraj S, Du Clos TW, Jialal I. The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res. 2007; 48: 509–512.[Abstract/Free Full Text]
  26. Vongpatanasin W, Thomas GD, Schwartz R, Cassis LA, Osborne-Lawrence S, Hahner L, Gibson LL, Black S, Samols D, Shaul PW. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation. 2007; 115: 1020–1028.[Abstract/Free Full Text]
  27. Teoh H, Quan A, Tirgari S, Lovren F, Wang G, Szmitko PE, Szalai AJ, Ward ME, Verma S. Impaired endothelial function in human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol. (submitted).
  28. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, Fay WP, Simon DI, Edelman ER. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation. 2003; 108: 512–515.[Abstract/Free Full Text]
  29. Paul A, Ko K, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004; 109: 647–655.[Abstract/Free Full Text]
  30. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2005; 102: 8309–8314.[Abstract/Free Full Text]
  31. Torzewski J. C-reactive protein and atherogenesis. New insights from established animal models. Am J Pathol. 2005; 167: 923–925.[Free Full Text]
  32. Grad E, Golomb M, Mor Yosef I, Koroukhov N, Lotan C, Edelman ER, Danenberg HD Transgenic expression of human C-reactive protein suppresses endothelial nitric oxide synthase expression and bioactivity following vascular injury. Am J Physiol Heart Circ Physiol. 2007. In press.
  33. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006; 440: 1217–1221.[CrossRef][Medline] [Order article via Infotrieve]

Related Article:

C-Reactive Protein Downregulates Endothelial NO Synthase and Attenuates Reendothelialization In Vivo in Mice
Randall Schwartz, Sherri Osborne-Lawrence, Lisa Hahner, Linda L. Gibson, Andrew K. Gormley, Wanpen Vongpatanasin, Weifei Zhu, R. Ann Word, Divya Seetharam, Steven Black, David Samols, Chieko Mineo, and Philip W. Shaul
Circ. Res. 2007 100: 1452-1459. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szmitko, P. E.
Right arrow Articles by Verma, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szmitko, P. E.
Right arrow Articles by Verma, S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NITRIC OXIDE
Related Collections
Right arrowRelated Article

Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.